Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최경규 | - |
dc.date.accessioned | 2016-08-28T12:08:19Z | - |
dc.date.available | 2016-08-28T12:08:19Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1823-6138 | - |
dc.identifier.other | OAK-8014 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/221985 | - |
dc.description.abstract | Catechol-O-methyltransferase (COMT) inhibitors are used to increase the bioavailability of therapeutic L-dopa. We examined the efficacy of entacapone in Parkinson's disease patients who had daily "off" duration of ≤2 hours, and carried different COMT polymorphisms. A total of 168 PD patients were recruited from 19 centers. Subjects were administered with 100-200 mg of entacapone in combination with each dose of L-dopa for 2 months. The clinical efficacy was evaluated based on the activities of daily living (ADL), score on the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) stage, and Clinical Global Impression (CGI). COMT polymorphisms were genotyped. 3-O-methyldopa (3-OMD) levels were measured before and after the administration of entacapone. Entacapone administration produced significant improvements in the total daily "on" duration, ADL, UPDRS score, and H&Y stage. Nineteen patients (11.3%) had the low-activity COMT genotype, 68 patients (40.5%) had the intermediate-activity COMT genotype, and 81patients (48.2%) had the high-activity COMT genotype. The efficacy, and adverse effects of entacapone therapy did not differ between the three groups. There was a significant reduction in 3-OMD, but this did not differ among the three genotypes. Entacapone provided an increased "on" duration and improved motor function in all COMT genotypes. | - |
dc.language | English | - |
dc.title | No correlation between COMT genotype and entacapone benefits in Parkinson's disease | - |
dc.type | Article | - |
dc.relation.issue | 3 | - |
dc.relation.volume | 16 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 211 | - |
dc.relation.lastpage | 216 | - |
dc.relation.journaltitle | Neurology Asia | - |
dc.identifier.wosid | WOS:000295410800006 | - |
dc.identifier.scopusid | 2-s2.0-80053467017 | - |
dc.author.google | Kim J.S. | - |
dc.author.google | Kim J.-Y. | - |
dc.author.google | Kim J.-M. | - |
dc.author.google | Kim J.W. | - |
dc.author.google | Chung S.J. | - |
dc.author.google | Kim S.R. | - |
dc.author.google | Kim M.J. | - |
dc.author.google | Kim H.-T. | - |
dc.author.google | Choi K.-G. | - |
dc.author.google | Shin D.-I. | - |
dc.author.google | Sung Y.H. | - |
dc.author.google | Lee K.-S. | - |
dc.author.google | Kim H.-J. | - |
dc.author.google | Cho J. | - |
dc.author.google | Park M.Y. | - |
dc.author.google | Park H.-Y. | - |
dc.author.google | Choi S.-M. | - |
dc.author.google | Park K.-W. | - |
dc.author.google | Lee H.-W. | - |
dc.author.google | Ahn T.-B. | - |
dc.author.google | Kwon O.D. | - |
dc.author.google | Kim S.-J. | - |
dc.author.google | Jeon B.S. | - |
dc.contributor.scopusid | 최경규(24472766200;37664619600) | - |
dc.date.modifydate | 20230616142633 | - |